Pharmaceuticals, Biotechnology and Life Sciences
SAN DIEGO–(BUSINESS WIRE)–Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today…
Top line results of Phase I study confirm favorable safety and tolerability of Trappsol® Cyclo™ in patients with NPC1 and…
Randomized, double-blind clinical study will test Hydroxychloroquine as a prophylactic treatment to prevent high-risk healthcare workers from contracting COVID-19 DANBURY,…
Presentation reports safety and efficacy results of INT230-6 administered alone and in combination with pembrolizumab (Keynote A10 study); safety of…
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies…
Trial conducted at Columbia University will investigate potential of chloroquine phosphate to prevent symptomatic SARS-CoV-2 infections EAST BRUNSWICK N.J.–(BUSINESS WIRE)–Rising…
Larry Green, PhD transitions from chief executive officer (CEO) to chairman, board of directors Justin Mika to succeed Dr. Green…
LYNPARZA was approved based on positive results from the PROfound study for which Foundation Medicine served as the Next-Generation Sequencing…
DUBLIN–(BUSINESS WIRE)–The “Agricultural Biotechnology – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering. The Agricultural Biotechnology…
Fourth-Quarter Highlights, Year-over-Year: Total revenues of $58.5 billion, reflecting 12% growth. Earnings per diluted share increased by $9.99 to $5.82.…